Deepa Bhanot, MD
Pulmonary Disease · Seaford, DENPI 1184936890
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 68 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 20 manufacturers reported payments, led by GSK at 27.1% of the total. Reporting peaked in 2019 at $488 and has fallen 56.0% since, to $215 in 2025. That places this record below the midpoint for pulmonary disease clinicians in DE, where the typical reported total is $1,477.
Across 68 payments — averaging $17.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$323
- Sunovion Pharmaceuticals Inc.$169
- Boehringer Ingelheim$103
- Sanofi$80
- AstraZeneca$56
- Genentech USA, Inc.$54
- plus $407 from 14 others
What the payments were for
- Food & beverage$1,194100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 19 | $323 |
| Sunovion Pharmaceuticals Inc. | 11 | $169 |
| Boehringer Ingelheim | 5 | $103 |
| Sanofi | 4 | $80 |
| AstraZeneca | 4 | $56 |
| Genentech USA, Inc. | 3 | $54 |
| Shire North American Group Inc | 3 | $51 |
| Philips North America LLC | 2 | $49 |
| Insmed, Inc. | 3 | $47 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $37 |
| Mylan Specialty L.p. | 2 | $36 |
| Grifols USA, LLC | 2 | $33 |
| Actelion Pharmaceuticals US, Inc. | 1 | $28 |
| Amgen | 1 | $23 |
| Novartis | 1 | $22 |
| AbbVie | 1 | $20 |
| Regeneron Healthcare Solutions, Inc. | 1 | $19 |
| Resmed Corp | 1 | $17 |
| Jazz Pharmaceuticals Inc. | 1 | $14 |
| Mallinckrodt Hospital Products Inc. | 1 | $13 |
How this compares
$1,194 in reported general payments places this provider in the 45th percentile of 39 pulmonary disease providers in Delaware.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 316 | $404,189 |
| OfevNintedanib Esylate | 12 | $158,154 |
| Pirfenidone | 49 | $143,138 |
| Breo ElliptaFluticasone/Vilanterol | 134 | $106,554 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 100 | $100,181 |
| Dupixent PenDupilumab | 26 | $96,213 |
| Advair HfaFluticasone Propion/Salmeterol | 77 | $65,746 |
| Arnuity ElliptaFluticasone Furoate | 155 | $60,523 |
| TezspireTezepelumab-Ekko | 13 | $50,214 |
| Incruse ElliptaUmeclidinium Bromide | 38 | $33,943 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 19 | $29,661 |
| EliquisApixaban | 20 | $28,631 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 31 | $25,120 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 35 | $14,565 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 253 | $13,508 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Arnuity Ellipta, Incruse Ellipta | $323 | $705,390743 claims |
| Boehringer IngelheimOfev, Stiolto Respimat | $103 | $183,27443 claims |
| AstraZenecaTezspire, Breztri Aerosphere, Symbicort | $56 | $85,90344 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 39 pulmonary disease providers in Delaware.
Other pulmonary disease in Seaford
- Nourhan KikaSeaford$3K
- Mark GranadaSeaford$171
- Victor BanzonLewes$300K
- Albert RizzoNewark$162K
- Michel SamahaMilford$94K
- Haroon RajaNewark$44K
- Ismael MatusNewark$27K
- Vikas BatraLewes$17K
- Ercilia AriasLewes$11K
- David JawaharDover$9K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.